H G H FRAGMENT

Price:

14,434.96 LE


GERIOSTIM 100
GERIOSTIM 100
13,391.20 LE
14,879.11 LE (10% OFF)
SOMAGEN AQUA
SOMAGEN AQUA
12,436.27 LE
13,818.08 LE (10% OFF)

H G H FRAGMENT -Human Growth Hormone 176-191 -2 MG / VIAL -10 VIALS

https://gorama.org/web/image/product.template/7173/image_1920?unique=cc4a4eb

14,434.96 LE 14434.957738151224 EGP 16,038.84 LE

325.00

Not Available For Sale


  • Brands

This combination does not exist.


Description:
Human Growth Hormone 176-191
Dosage:
2 MG / VIAL
Quantity:
10 VIALS
Weight:
0.11000 KG

Share :
100% original guarantee
Return within 30days
Free delivery on all orders
  • HGH Fragment 176-191 is a small, synthetic piece of natural human growth hormone (hGH). It is often referred to as the “lipolytic fragment” for its ability to boost fat loss. It has been shown to help lower blood sugar levels and promote cartilage healing without increasing long bone growth, increasing IGF-1 levels, or altering insulin sensitivity. 


  • Fragment 176-191 (modified version of AOD9604) is a small piece of human growth hormone (hGH) that is sometimes referred to as the "lipolytic fragment." Fragment 176-191 earned this latter name due to the fact that laboratory research has shown it to enhance fat burning, particularly in mice genetically engineered to produce large fat stores. Fragment 176-191 has been heavily researched in animal models because even while it preserves the fat-burning effects of hGH, it avoids some other effects of its parent protein such as increasing insulin-like growth factor-1 (IGF-1) levels, negatively impacting carbohydrate metabolism, altering insulin sensitivity, increasing long bone growth, and so forth. The targeted effects of fragment 176-191 make it useful for exploring human fat metabolism and may eventually provide the basis for developing anti-obesity medications. 

  • Sequence : Tyr-Leu-Arg-Ile-Val-Gin-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe.
  •  Molecular Formula: C78H125N23023S2 .
  • Molecular Weight: 1817.12 g/mol CAS Number: 66004-57-7


  • What Is Fragment 176-191?

  • Fragment 176-191 (modified version of AOD9604) is a small piece of human growth hormone (hGH) that is sometimes referred to as the “lipolytic fragment.” Fragment 176-191 earned this latter name due to the fact that laboratory research has shown it to enhance fat burning, particularly in mice genetically engineered to produce large fat stores. Fragment 176-191 has been heavily researched in animal models because even while it preserves the fat-burning effects of hGH, it avoids some other effects of its parent protein such as increasing insulin-like growth factor-1 (IGF-1) levels, negatively impacting carbohydrate metabolism, altering insulin sensitivity, increasing long bone growth, and so forth. The targeted effects of fragment 176-191 make it useful for exploring human fat metabolism and may eventually provide the basis for developing anti-obesity medications.
  • Fragment 176-191 Peptide Structure

  • Source: PubChem
  • Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
  • Molecular Formula: C78H125N23O23S2
  • Molecular Weight: 1817.12 g/mol
  • CAS Number: 66004-57-7
  • Fragment 176-191 Effects

  • 1. Lowers Blood Sugar

  • Research in animals has revealed that the c-terminal end of hGH is primarily responsible for the protein’s hypoglycemic (lowering blood sugar) effects. Testing of at least six different fragments derived from this section of hGH has shown that fragment 176-191 is the most effective synthetic derivative of hGH for lowering blood sugar levels. This effect is secondary to a sustained increase in plasma insulin levels[1]. There is some interest in using fragment 176-191 as a treatment for both prediabetes and type 2 diabetes.
  • 2. Fat Burning And Weight Loss

  • Fragment 176-191 has earned the nickname of “lipolytic fragment” because testing in mice has revealed the peptide to have substantial fat burning and weight loss properties. It is thought that this action is mediated through an increase in production of beta-3 adrenergic receptors (β3-AR or ADRB3)[2]. Agonist action at ADRB3 is known to directly increase fat burning in adipose tissue and is also responsible for thermogenesis in skeletal muscle[3]. Mice that have been genetically modified to produce no ADRB3 do not respond to the lipolytic effects of hGH or fragment 176-191[2].
  • Studies show that the increased fat burning associated with fragment 176-191 directly correlates with energy expenditure and thus weight reduction, leading to a nearly 50% reduction in weight gain in obese animals over a three-week course[4]. Interestingly, the weight loss effects were seen only in obese mice, with lean mice maintaining normal body weight, on average, even when exposed to fragment 176-191[2]. These findings indicate that there are secondary regulatory pathways for lipolysis that override ADRB3 function when body weight is at or near ideal, opening up areas for additional research into energy homeostasis.


  •  fragment 176-191
  • Source: Oxford Academic
  • The results of this meta-analysis suggest that fragment 176-191 offers many of the benefits of hGH without the associated negative (and often serious) side effects. These findings further the argument for pursuing regulatory approval for use of fragment 176-191 in the clinical setting, but also offer insight into the regulation of human growth, fat deposition, and energy homeostasis. These findings make it clear that it is possible to target fat loss without affecting energy homeostasis in other nutrient pathways, opening the door for a deeper exploration of human energy regulation and methods of manipulating it.


  • It is worth noting that while hGH has anabolic effects on muscle, fragment 176-191 was specifically selected for its ability to avoid anabolism entirely. This is critical to ensuring that the peptide has targeted lipolytic effects and does not produce acromegaly or any of the other conditions associated with hGH administration. Studies reveal that fragment 176-191 does not increase cell proliferation[6].
  • Fragment 176-191 Future Research

  • The primary area of research for fragment 176-191 is in weight loss and lipolysis where significant effort is being expended to learn how the peptide can be used to understand fat metabolism and energy homeostasis. The most active secondary area of research is in connective tissue regeneration, particularly cartilage repair.


Brands Thaiger Pharma